Spruce Biosciences Highlights Promising Long-Term Tralesinidase Data

Spruce Biosciences ( (SPRB) ) has issued an update.

On February 5, 2026, Spruce Biosciences reported long-term clinical data presented at the 22nd Annual WORLDSymposium showing that its investigational tralesinidase alfa enzyme replacement therapy (TA-ERT) produced rapid and durable reductions in heparan sulfate levels and preserved cognitive and non-cognitive functions in patients with Sanfilippo Syndrome Type B (MPS IIIB) compared with untreated natural history patients over a follow-up period of up to six years. Across 22 treated patients, weekly TA-ERT normalized a key cerebrospinal fluid biomarker (HS-NRE), stabilized cognitive performance, cortical gray matter volume, and liver and spleen size, and maintained receptive and expressive communication and fine and gross motor skills as measured by validated developmental and adaptive behavior scales, while exhibiting a safety profile consistent with intracerebroventricular administration over roughly 6,000 doses. A case study comparing two siblings with severe MPS IIIB, one treated with TA-ERT and one untreated, highlighted a marked divergence in language, self-care, and motor abilities in favor of the treated child, underscoring the potential for TA-ERT to alter the course of this fatal, currently untreatable disease and reinforcing Spruce’s positioning as a developer of first-in-class, disease-modifying therapies in the ultra-rare neurology space.

The most recent analyst rating on (SPRB) stock is a Hold with a $86.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.

Spark’s Take on SPRB Stock

According to Spark, TipRanks’ AI Analyst, SPRB is a Neutral.

The score is primarily held down by weak financial performance (large losses, heavy cash burn, and declining revenue) and bearish-to-neutral technical signals (below key short/intermediate moving averages with negative MACD). Recent financing events modestly improve liquidity/runway, but they do not offset the current loss profile and cash burn.

To see Spark’s full report on SPRB stock, click here.

More about Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, including investigational treatments for ultra-rare genetic conditions such as Sanfilippo Syndrome Type B (MPS IIIB).

Average Trading Volume: 87,764

Technical Sentiment Signal: Buy

Current Market Cap: $84.81M

Learn more about SPRB stock on TipRanks’ Stock Analysis page.